HTBX - Heat Biologics shares rise ahead of upcoming HS-110 ASCO data

Heat Biologics (HTBX) announces that the latest data from HS-110, the company’s lead product, has been accepted for poster presentation at the 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting, to be held next month.Shares up more than 12% premarket.HS-110 is a first-in-class, off-the-shelf, allogeneic cell therapy designed to utilize gp96 for immune activation against multiple tumor testis antigens.The therapy has broad potential for providing multiple treatment options to non-small cell lung cancer ((NSCLC)) patients in combination with a PD-1 inhibitor, the company said.The abstract to be presented at ASCO is titled "Interim results of viagenpumatucel-L (HS-110) plus nivolumab in previously treated patients with advanced non-small cell lung cancer ((NSCLC)) in two treatment settings".The company added that positive interim survival data has been shown by HS-110 in two distinct treatment settings in certain previously treated NSCLC patients.#ASCO21

For further details see:

Heat Biologics shares rise ahead of upcoming HS-110 ASCO data